The information was submitted for publication 2017-07-04 at 08.20
On July 18, 2017, at 08:20 publish CellaVision AB (publ) interim report for the second quarter of 2017. The report will be available on the www.cellavision.se
In this connection, invited analysts, investors and media to a audiosänd conference call the same day at 11:00, where president and CEO, Miletic Rihter, will present and comment the report.
The presentation will be conducted in English via a telephone conference or audiosändning on:
https://tv.streamfabriken.com/cellavision-q2-report
Phone number to the conference:
SEE: +46 8 56 642 666
UK: +44 2 030 089 802
US: +1 8 558 315 945
No registration is required. Please call in to the conference 5-10 minutes before the scheduled start time in order to facilitate the start at the appointed time.
About CellaVision
CellaVision is an innovative, global medical device company that develops and sells leading systems for routine analysis of blood and other body fluids in health care. The analyses often constitute important basis for the timely and accurate sjukdomsdiagnoser, for example in infections and serious cancers. CellaVisions products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. Expertise is in image analysis, artificial intelligence and automated microscopy. Sales through global partners with support from the parent company in Lund, as well as marketing organizations in the united states, Canada, China, Sweden, Japan, Dubai, south Korea, France, Australia, Germany and Brazil. 2016, the turnover was Sek 265. The share is listed on Nasdaq Stockholm, Small Cap. Read more on www.cellavision.se
